Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Sells $33,592.14 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 2,586 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $12.99, for a total value of $33,592.14. Following the transaction, the insider now directly owns 44,746 shares in the company, valued at $581,250.54. This trade represents a 5.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Barry Ticho also recently made the following trade(s):

• On Friday, December 6th, Barry Ticho sold 13,945 shares of Stoke Therapeutics stock. The shares were sold at an average price of $12.78, for a total transaction of $178,217.10.
• On Monday, December 2nd, Barry Ticho sold 10,000 shares of Stoke Therapeutics stock. The shares were sold at an average price of $12.07, for a total transaction of $120,700.00.

Stoke Therapeutics Trading Down 2.1 %

Shares of STOK opened at $12.06 on Friday. The firm has a market cap of $638.82 million, a price-to-earnings ratio of -5.74 and a beta of 0.95. Stoke Therapeutics, Inc. has a 52 week low of $4.09 and a 52 week high of $17.58. The stock has a 50 day moving average of $12.49 and a 200-day moving average of $13.65.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.05. The firm had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, sell-side analysts predict that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Stoke Therapeutics

Institutional investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD boosted its stake in Stoke Therapeutics by 5.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 31,431 shares of the company’s stock valued at $425,000 after acquiring an additional 1,642 shares during the period. SG Americas Securities LLC boosted its position in Stoke Therapeutics by 610.3% during the 2nd quarter. SG Americas Securities LLC now owns 68,601 shares of the company’s stock valued at $927,000 after purchasing an additional 58,943 shares during the period. Assenagon Asset Management S.A. bought a new position in Stoke Therapeutics during the 2nd quarter worth $19,835,000. Nisa Investment Advisors LLC increased its position in Stoke Therapeutics by 53.2% in the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after buying an additional 1,038 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in Stoke Therapeutics by 28.9% in the second quarter. Bank of New York Mellon Corp now owns 115,892 shares of the company’s stock valued at $1,566,000 after buying an additional 25,988 shares during the last quarter.

Analysts Set New Price Targets

STOK has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday. Leerink Partners began coverage on Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price on the stock. Finally, Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Stoke Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $20.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.